482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dntgfβrii-Armoured Steap2-Targeted Autologous Car T-Cell Prostate Cancer	Shanghai AbelZeta Ltd.	P1	C (36)
dxc008 Prostate Cancer	Hangzhou DAC Biotechnology Co., Ltd.	P1	C (36)
dxc014 Prostate Cancer	Hangzhou DAC Biotechnology Co., Ltd.	P1	C (36)
Ethylicum Prostate Cancer	Icahn School of Medicine at Mount Sinai	P1	C (36)
exs74539 Prostate Cancer	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1	C (36)
Hrs-9815 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1	C (36)
Ide-161 Prostate Cancer	IDEAYA Biosciences	P1	C (36)
Idov-Immune Prostate Cancer	ViroMissile, Inc.	P1	C (36)
Janx007 Prostate Cancer	Janux Therapeutics	P1	C (36)
Janx014 Prostate Cancer	Janux Therapeutics	P1	C (36)
ly4052031 Prostate Cancer	Eli Lilly and Company	P1	C (36)
ly4101174 Prostate Cancer	Eli Lilly and Company	P1	C (36)
Mdpk67B Prostate Cancer	Med Discovery SA	P1	C (36)
Moma-313 Prostate Cancer	MOMA Therapeutics	P1	C (36)
Naptumomab Estafenatox Prostate Cancer	NeoTX Therapeutics Ltd.	P1	C (36)
ngm438 Prostate Cancer	NGM Biopharmaceuticals, Inc	P1	C (36)
ngm831 Prostate Cancer	NGM Biopharmaceuticals, Inc	P1	C (36)
NORVIR Prostate Cancer	University of Chicago	P1	C (36)
-Nota-Psmai-Peg-Cy5.5-C' Dot Tracer Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1	C (36)
Nuv-868 Prostate Cancer	Nuvation Bio Inc.	P1	C (36)
Obinutuzumab Prostate Cancer	NeoTX Therapeutics Ltd.	P1	C (36)
Oct-598 Prostate Cancer	Oscotec Inc.	P1	C (36)
Ovm-200 Prostate Cancer	Oxford Vacmedix UK Ltd.	P1	C (36)
Pgv-001 Prostate Cancer	Ashutosh Kumar Tewari	P1	C (36)
Psma-Targeted [In-111]-Labeled Trillium Compound Prostate Cancer	Ratio Therapeutics, Inc.	Early P1	C (36)
Psw-1025 Prostate Cancer	Osaka University	P1	C (36)
Pti-122 Prostate Cancer	Ratio Therapeutics, Inc.	Early P1	C (36)
QXL138AM Prostate Cancer	Nammi Therapeutics Inc	P1	C (36)
Stm-416P Prostate Cancer	SURGE Therapeutics	P1	C (36)
syn818 Prostate Cancer	Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	P1	C (36)
Telmisartan Prostate Cancer	Tyler J Curiel	P1	C (36)
TH19P01-DOCETAXEL Prostate Cancer	Theratechnologies	P1	C (36)
tj101 Prostate Cancer	Phrontline Biopharma	P1	C (36)
Unicar02-T-Ppsma Prostate Cancer	AvenCell Therapeutics, Inc.	P1	C (36)
Xaluritamig Prostate Cancer	Amgen	P1	C (36)
Xentuzumab Prostate Cancer	University of Oxford	Early P1	C (36)
YS5 antibody Prostate Cancer	Robert Flavell, MD, PhD	P1	C (36)
Zirconium Zr 89-Dfo-Ys5 Prostate Cancer	Robert Flavell, MD, PhD	P1	C (36)
zm008 Prostate Cancer	Zumutor Biologics Inc.	P1	C (36)
177lu-labeled ny108 Prostate Cancer	Affiliated Hospital of Jiangnan University	Early P1	C (33)
[18f]alf-psma-n5 Prostate Cancer	Anhui Provincial Hospital	Early P1	C (33)
[18f]f-psma-n5 Prostate Cancer	Anhui Provincial Hospital	Early P1	C (33)
⁶⁸ga-fc516 Prostate Cancer	FindCure Biosciences (ZhongShan) Co., Ltd.	Early P1	C (33)
[68Ga]Ga-PSMA-D5 Prostate Cancer	Anhui Provincial Hospital	Early P1	C (33)
68Ga-RGD Prostate Cancer	Peking Union Medical College Hospital	Early P1	C (33)
68ga-rm26-rgd Prostate Cancer	Peking Union Medical College Hospital	Early P1	C (33)
Apple Cider Vinegar Prostate Cancer	Western University	Early P1	C (33)
Lisinopril Prostate Cancer	University of Rochester	Early P1	C (33)
Tazverik Prostate Cancer	Edwin Posadas, MD	Early P1	C (33)
Tirzepatide Prostate Cancer	M.D. Anderson Cancer Center	Early P1	C (33)

Showing 401 to 450 of 482 assets

PreviousPage 9 of 10Next